learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 801 resultslearn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Setipiprant
learn pyrrolidone carboxylic acid
learn phenoxyethanol
Research
5 / 1000+ results
research Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease
A woman with Parkinson's disease experienced hair loss from the Parkinson's medication pramipexole, which improved after stopping the drug.
research Alopecia induced by dopamine agonists
Dopamine agonists like pramipexole and ropinirole can cause reversible hair loss.
research Prednisolone
A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.
research Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
Pregnenolone might help manage movement issues caused by Parkinson's disease treatment without reducing the medicine's effectiveness.
research Finasteride Attenuates Pathological Gambling in Patients With Parkinson Disease
Finasteride reduces gambling symptoms in Parkinson's patients.
Community Join
5 / 1000+ resultscommunity 4 months, oral min fin, chewable
The user experienced hair regrowth using a chewable combination of oral minoxidil and finasteride without side effects, unlike when taken separately. The treatment is from Hims, and the user is satisfied with the progress, especially on the crown.
community Updates on setipiprant, bimatoprost?
community Setipiprant/PGE2 feedbacks?
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Currently participating in the Extended Phase III clinical trial of Pyrilutamid in China
A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.